CellProtect Nordic Pharmaceuticals AB participates in the SWElife’s project on Advanced Therapy Medicinal Products (ATMPs)
SWElife’sATMP project focuses on business development based on health economics, value-based health care and the available infrastructures within Sweden. The goal is to strengthen Sweden’s position in the international field of ATMPs.
CellProtect Nordic Pharmaceuticals AB is one of 14 project partners representing both academia and public bodies as well as the private sector. The partners will contribute with their expertise to pave the way for these pharmaceuticals to the patient’s bedside.
Karin Mellström will represent CellProtect Nordic Pharmaceuticals AB in the coming discussions.
“We are very happy to participate in this work that may have a significant impact on patients with severe, currently incurable, diseases” says Karin Mellström, CEO of CellProtect Nordic Pharmaceuticals AB
Read more about the project on SWElife homepage (Swedish):